Gene-Chemical Interaction Annotations Click to see Annotation Detail View
Object Symbol | Species | Term | Qualifier | Evidence | With | Reference | Notes | Source | Original Reference(s) | Fbxo16 | Mouse | 17beta-estradiol | multiple interactions | ISO | Fbxo16 (Rattus norvegicus) | 6480464 | [estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in decreased expression of FBXO16 mRNA | CTD | PMID:32741896 | Fbxo16 | Mouse | 17beta-estradiol | decreases expression | ISO | FBXO16 (Homo sapiens) | 6480464 | Estradiol results in decreased expression of FBXO16 mRNA | CTD | PMID:31614463 | Fbxo16 | Mouse | 17beta-estradiol 3-benzoate | multiple interactions | ISO | Fbxo16 (Rattus norvegicus) | 6480464 | [estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in decreased expression of FBXO16 mRNA | CTD | PMID:32741896 | Fbxo16 | Mouse | 2,2',4,4'-Tetrabromodiphenyl ether | increases expression | ISO | FBXO16 (Homo sapiens) | 6480464 | 2 more ... | CTD | PMID:19095052 | Fbxo16 | Mouse | 2,3,7,8-tetrachlorodibenzodioxine | affects expression | ISO | Fbxo16 (Rattus norvegicus) | 6480464 | Tetrachlorodibenzodioxin affects the expression of FBXO16 mRNA | CTD | PMID:22298810 | Fbxo16 | Mouse | 2,3,7,8-tetrachlorodibenzodioxine | increases expression | ISO | Fbxo16 (Rattus norvegicus) | 6480464 | Tetrachlorodibenzodioxin results in increased expression of FBXO16 mRNA | CTD | PMID:33387578 | Fbxo16 | Mouse | 4,4'-diaminodiphenylmethane | decreases expression | EXP | | 6480464 | 4 and 4'-diaminodiphenylmethane results in decreased expression of FBXO16 mRNA | CTD | PMID:18648102 | Fbxo16 | Mouse | aflatoxin B1 | decreases expression | ISO | FBXO16 (Homo sapiens) | 6480464 | Aflatoxin B1 results in decreased expression of FBXO16 mRNA | CTD | PMID:22100608 | Fbxo16 | Mouse | all-trans-retinoic acid | decreases expression | ISO | FBXO16 (Homo sapiens) | 6480464 | Tretinoin results in decreased expression of FBXO16 mRNA | CTD | PMID:33167477 | Fbxo16 | Mouse | amiodarone | increases expression | ISO | FBXO16 (Homo sapiens) | 6480464 | Amiodarone results in increased expression of FBXO16 mRNA | CTD | PMID:19774075 | Fbxo16 | Mouse | bisphenol A | increases methylation | ISO | Fbxo16 (Rattus norvegicus) | 6480464 | bisphenol A results in increased methylation of FBXO16 gene | CTD | PMID:28505145 | Fbxo16 | Mouse | bisphenol A | multiple interactions | ISO | FBXO16 (Homo sapiens) | 6480464 | [bisphenol A co-treated with Fulvestrant] results in decreased methylation of FBXO16 gene | CTD | PMID:31601247 | Fbxo16 | Mouse | bisphenol A | decreases methylation | ISO | FBXO16 (Homo sapiens) | 6480464 | bisphenol A results in decreased methylation of FBXO16 gene | CTD | PMID:31601247 | Fbxo16 | Mouse | butanal | increases expression | ISO | FBXO16 (Homo sapiens) | 6480464 | butyraldehyde results in increased expression of FBXO16 mRNA | CTD | PMID:26079696 | Fbxo16 | Mouse | cadmium dichloride | decreases expression | ISO | FBXO16 (Homo sapiens) | 6480464 | Cadmium Chloride results in decreased expression of FBXO16 mRNA | CTD | PMID:38382870 | Fbxo16 | Mouse | chlordecone | decreases expression | EXP | | 6480464 | Chlordecone results in decreased expression of FBXO16 mRNA | CTD | PMID:33711761 | Fbxo16 | Mouse | copper(II) sulfate | decreases expression | ISO | FBXO16 (Homo sapiens) | 6480464 | Copper Sulfate results in decreased expression of FBXO16 mRNA | CTD | PMID:19549813 | Fbxo16 | Mouse | Cuprizon | increases expression | ISO | Fbxo16 (Rattus norvegicus) | 6480464 | Cuprizone results in increased expression of FBXO16 mRNA | CTD | PMID:26577399 | Fbxo16 | Mouse | cyclosporin A | increases expression | ISO | FBXO16 (Homo sapiens) | 6480464 | Cyclosporine results in increased expression of FBXO16 mRNA | CTD | PMID:20106945 more ... | Fbxo16 | Mouse | dibutyl phthalate | decreases expression | EXP | | 6480464 | Dibutyl Phthalate results in decreased expression of FBXO16 mRNA | CTD | PMID:21266533 | Fbxo16 | Mouse | dorsomorphin | multiple interactions | ISO | FBXO16 (Homo sapiens) | 6480464 | [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... | CTD | PMID:27188386 | Fbxo16 | Mouse | endosulfan | decreases expression | ISO | Fbxo16 (Rattus norvegicus) | 6480464 | Endosulfan results in decreased expression of FBXO16 mRNA | CTD | PMID:29391264 | Fbxo16 | Mouse | entinostat | increases expression | ISO | FBXO16 (Homo sapiens) | 6480464 | entinostat results in increased expression of FBXO16 mRNA | CTD | PMID:27188386 | Fbxo16 | Mouse | ethyl methanesulfonate | increases expression | ISO | FBXO16 (Homo sapiens) | 6480464 | Ethyl Methanesulfonate results in increased expression of FBXO16 mRNA | CTD | PMID:23649840 | Fbxo16 | Mouse | formaldehyde | decreases expression | ISO | FBXO16 (Homo sapiens) | 6480464 | Formaldehyde results in decreased expression of FBXO16 mRNA | CTD | PMID:27905399 | Fbxo16 | Mouse | fulvestrant | multiple interactions | ISO | FBXO16 (Homo sapiens) | 6480464 | [bisphenol A co-treated with Fulvestrant] results in decreased methylation of FBXO16 gene | CTD | PMID:31601247 | Fbxo16 | Mouse | hydroquinone O-beta-D-glucopyranoside | increases expression | ISO | FBXO16 (Homo sapiens) | 6480464 | Arbutin results in increased expression of FBXO16 mRNA | CTD | PMID:17103032 | Fbxo16 | Mouse | kojic acid | increases expression | ISO | FBXO16 (Homo sapiens) | 6480464 | kojic acid results in increased expression of FBXO16 mRNA | CTD | PMID:16595896 | Fbxo16 | Mouse | lipopolysaccharide | decreases expression | ISO | FBXO16 (Homo sapiens) | 6480464 | Lipopolysaccharides results in decreased expression of FBXO16 mRNA | CTD | PMID:35811015 | Fbxo16 | Mouse | lipopolysaccharide | multiple interactions | ISO | FBXO16 (Homo sapiens) | 6480464 | [S-(1 and 2-dichlorovinyl)cysteine affects the susceptibility to Lipopolysaccharides] which results in increased expression of FBXO16 mRNA | CTD | PMID:35811015 | Fbxo16 | Mouse | methyl methanesulfonate | increases expression | ISO | FBXO16 (Homo sapiens) | 6480464 | Methyl Methanesulfonate results in increased expression of FBXO16 mRNA | CTD | PMID:23649840 | Fbxo16 | Mouse | methylmercury chloride | decreases expression | ISO | FBXO16 (Homo sapiens) | 6480464 | methylmercuric chloride results in decreased expression of FBXO16 mRNA | CTD | PMID:28001369 | Fbxo16 | Mouse | Monobutylphthalate | increases expression | ISO | Fbxo16 (Rattus norvegicus) | 6480464 | monobutyl phthalate results in increased expression of FBXO16 mRNA | CTD | PMID:29162477 | Fbxo16 | Mouse | paracetamol | decreases expression | ISO | Fbxo16 (Rattus norvegicus) | 6480464 | Acetaminophen results in decreased expression of FBXO16 mRNA | CTD | PMID:33387578 | Fbxo16 | Mouse | phenylmercury acetate | multiple interactions | ISO | FBXO16 (Homo sapiens) | 6480464 | [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBXO16 mRNA | CTD | PMID:27188386 | Fbxo16 | Mouse | S-(1,2-dichlorovinyl)-L-cysteine | multiple interactions | ISO | FBXO16 (Homo sapiens) | 6480464 | [S-(1 and 2-dichlorovinyl)cysteine affects the susceptibility to Lipopolysaccharides] which results in increased expression of FBXO16 mRNA | CTD | PMID:35811015 | Fbxo16 | Mouse | SB 431542 | multiple interactions | ISO | FBXO16 (Homo sapiens) | 6480464 | [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... | CTD | PMID:27188386 | Fbxo16 | Mouse | sodium arsenite | decreases expression | ISO | FBXO16 (Homo sapiens) | 6480464 | sodium arsenite results in decreased expression of FBXO16 mRNA | CTD | PMID:34032870 | Fbxo16 | Mouse | sodium arsenite | increases expression | EXP | | 6480464 | sodium arsenite results in increased expression of FBXO16 mRNA | CTD | PMID:37682722 | Fbxo16 | Mouse | sodium fluoride | increases expression | ISO | Fbxo16 (Rattus norvegicus) | 6480464 | Sodium Fluoride results in increased expression of FBXO16 mRNA | CTD | PMID:27257137 | Fbxo16 | Mouse | sunitinib | decreases expression | ISO | FBXO16 (Homo sapiens) | 6480464 | Sunitinib results in decreased expression of FBXO16 mRNA | CTD | PMID:31533062 | Fbxo16 | Mouse | testosterone | multiple interactions | ISO | Fbxo16 (Rattus norvegicus) | 6480464 | [estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in decreased expression of FBXO16 mRNA | CTD | PMID:32741896 | Fbxo16 | Mouse | trichloroethene | increases expression | ISO | Fbxo16 (Rattus norvegicus) | 6480464 | Trichloroethylene results in increased expression of FBXO16 mRNA | CTD | PMID:33387578 | Fbxo16 | Mouse | trichostatin A | decreases expression | ISO | FBXO16 (Homo sapiens) | 6480464 | trichostatin A results in decreased expression of FBXO16 mRNA | CTD | PMID:24935251 and PMID:26272509 | Fbxo16 | Mouse | trichostatin A | affects expression | ISO | FBXO16 (Homo sapiens) | 6480464 | trichostatin A affects the expression of FBXO16 mRNA | CTD | PMID:28542535 | Fbxo16 | Mouse | trichostatin A | multiple interactions | ISO | FBXO16 (Homo sapiens) | 6480464 | [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBXO16 mRNA | CTD | PMID:27188386 | Fbxo16 | Mouse | triptonide | increases expression | EXP | | 6480464 | triptonide results in increased expression of FBXO16 mRNA | CTD | PMID:33045310 | Fbxo16 | Mouse | tunicamycin | increases expression | ISO | FBXO16 (Homo sapiens) | 6480464 | Tunicamycin results in increased expression of FBXO16 mRNA | CTD | PMID:22378314 | Fbxo16 | Mouse | valproic acid | decreases methylation | ISO | FBXO16 (Homo sapiens) | 6480464 | Valproic Acid results in decreased methylation of FBXO16 gene | CTD | PMID:29154799 | Fbxo16 | Mouse | valproic acid | multiple interactions | ISO | FBXO16 (Homo sapiens) | 6480464 | [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBXO16 mRNA | CTD | PMID:27188386 | Fbxo16 | Mouse | valproic acid | decreases expression | ISO | FBXO16 (Homo sapiens) | 6480464 | Valproic Acid results in decreased expression of FBXO16 mRNA | CTD | PMID:23179753 and PMID:26272509 | Fbxo16 | Mouse | valproic acid | increases expression | ISO | FBXO16 (Homo sapiens) | 6480464 | Valproic Acid results in increased expression of FBXO16 mRNA | CTD | PMID:29154799 | Fbxo16 | Mouse | valproic acid | affects expression | ISO | FBXO16 (Homo sapiens) | 6480464 | Valproic Acid affects the expression of FBXO16 mRNA | CTD | PMID:25979313 | Fbxo16 | Mouse | vinclozolin | increases expression | ISO | Fbxo16 (Rattus norvegicus) | 6480464 | vinclozolin results in increased expression of FBXO16 mRNA | CTD | PMID:22570695 | Fbxo16 | Mouse | vorinostat | multiple interactions | ISO | FBXO16 (Homo sapiens) | 6480464 | [NOG protein co-treated with Vorinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBXO16 mRNA | CTD | PMID:27188386 | Fbxo16 | Mouse | vorinostat | decreases expression | ISO | FBXO16 (Homo sapiens) | 6480464 | vorinostat results in decreased expression of FBXO16 mRNA | CTD | PMID:26272509 | |